BE 16627B

Drug Profile

BE 16627B

Latest Information Update: 01 Jul 2003

Price : $50

At a glance

  • Originator Banyu
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Rheumatoid arthritis

Most Recent Events

  • 08 Aug 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 25 Feb 1999 No-Development-Reported for Rheumatoid arthritis in Japan (Unknown route)
  • 26 Jan 1996 A preclinical study has been added to the Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top